The Second Golden Era of #MPN Drug Development: EHA 2026 Updates | EHA 2026

Dr. Naveen Pemmaraju provides an exciting overview of major advances in myeloproliferative neoplasm (MPN) treatment at the European Hematology Association (EHA) 2026 meeting. Highlighting a second golden era of MPN drug development with three transformative approaches.

THREE MAJOR AREAS OF ADVANCEMENT:

1. TYPE 2 JAK INHIBITORS - JAK2 Mutation Targeting
Evolution from type 1 to type 2 JAK inhibitors with more selective, mutation-specific pathway targeting. First clinical data presented at EHA 2026.

2. CALR MUTATION TARGETING - Second Most Common MPN Driver
CALR mutation discovered in 2013. First-in-human phase 1/2 trials underway using small molecules, monoclonal antibodies, bispecifics, and potential CAR-T cells.

3. HEPCIDIN PATHWAY MODULATION - Polycythemia Vera Treatment
Addresses iron homeostasis abnormality in PV. Lead agent: Luspatercept with phase 3 positive results. Expected availability within 1 year. Additional drugs in development.

A personal message from Dr. Pemmaraju about advocacy for patients facing rare blood cancers.

Learn more: https://linktr.ee/HealthTreeUniversity

TIMESTAMPS:
0:00 Introduction & The Second Golden Era
0:11 First Golden Era: JAK-STAT Pathway
0:19 Three Major Areas of Advancement
0:27 Area 1: Type 2 JAK Inhibitors
0:34 JAK2 Mutation-Selective Targeting
0:43 First Clinical Data at EHA 2026
0:51 Area 2: CALR Mutation Targeting
1:00 CALR Discovery & Current Development
1:08 Multiple Therapeutic Approaches
1:15 Monoclonal Antibodies & Bispecifics
1:23 Potential Future: CAR-T Cell Therapy
1:30 Area 3: Hepcidin Pathway & PV
1:36 Iron Homeostasis in Polycythemia Vera
1:45 Luspatercept & Iron Balance
1:57 Phase 3 Data & Timeline
2:07 Future Hepcidin-Targeting Drugs
2:16 Patient Advocacy & Commitment
2:23 Closing Message

#MPN #JAK #CALR #PolycythemiaVera #EHA2026